A Multidisciplinary Project

Studying the production of innovative RadioIsotopes through ISOL technique for medical applications.

Latest news from ISOLPHARM

ISOLPHARM on Nuclear Physics News International

We are happy to announce the pubblication on the NuPECC journal “Nuclear Physics News Internation” of a general article onISOLPHARM named: “The ISOLPHARM Project: Production of HighSpecific Activity Medical Radioisotopes[…]

Read more

Task 3 gets to the target

Task 3 activities are currently accelerating towards the selection and development of an efficient in-vitro model overexpressing CCK2R. Measurements of the intracellular calcium increase upon stimulation of the receptor were successfully performed, thus leading to an optimized tumor model which will be further tested in 3D scaffolds.

Read more

ISOLPHARM at SIRR 2020

The XIX National Congress SIRR 2020 was organized by Società Italiana per le Ricerche sulle Radiazioni (SIRR) as an online conference from 10th to 12th November 2020. The most advanced research topics in the fields of radiation applications, radioprotection, medical and industrial uses of radiation were presented with a multisciplinar approach, involving aspetcs in Physics, Biology, Engineering, Chemistry and Medicine.

Read more

A Large Collaboration
Between Universities
and Research Centers

The ISOLPHARM Project was born from the collaboration between the Departments of Pharmaceutical and Pharmacological, Department of Chemical Sciences of the University of Padova and the Legnaro National Laboratories (LNL) of the National Institute of Nuclear Physics (INFN) where the Selective Production of Exotic Specie (SPES) project in under development. By means, of Isotope Separation On-Line technique both traditional and innovative radioisotopes will be produced with high-specific activity, going beyond the state-of-art of the radioisotope production.

Read more

Strengths and key features

The key features of ISOLPHARM are: a) the presence of a strong local collaboration between INFN-LNL, INFN-PD, INFN-PV, TIFPA, UNIPD and UNIBS in many fields of research, ranging from the production of the RIBs to the employment of the radionuclides. b) the ISOL technique, which can easily provide high specific activity radionuclides. c) the INFN patent, which proves the innovation and excellence of the project. d) the low environmental and social impact, since nuclear reactors are not used for the provision of the radionuclides, which traditionally may be obtained irradiating massive amount of materials, that lately become tons of nuclear wastes.

Advantages

VERSATILITY

Production of a large set of radionuclides carrier-free and with large radionuclide purity

INNOVATIVITY

Many unconventional radioisotopes (short T 1/2) difficult to produce with traditional techniques

FLEXIBILITY

On-line mass selection by tuning the separator; easy production of different radionuclides 

GREEN

Low production of radioative waste material

2020-2022 Project

ISOLPHARM_EIRA

The future for radiopharmaceutical production at ISOLPHARM